LEO Pharma Announces European Commission Approval of Adtralza® (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents
Adtralza, a biologic that targets and neutralizes the interleukin (IL)-13 cytokine1, is now approved in Europe for adolescents with moderate-to-severe atopic dermatitis.2 NOT FOR DISTRIBUTION IN THE